


THE VALUE LINE
INVESTMENT
SURVEY
SMALL & MID-CAP
EDITION
SAMPLE PAGE

-
1. Here is the core of Value Line's advice: the rank for Performance,TM the technical rank; the rank for Safety;TM Beta—the stock's sensitivity to fluctuations of the market as a whole.
 2. Value Line's Indexes of Financial Strength, Price Stability, Price Growth Persistence, and Earnings Predictability.
 3. Statistical milestones that reveal significant long-term trends. The statistics are presented in two ways: 1) the upper series records results on a per-share basis; 2) the lower records results on a company basis.
 4. **Footnote A-** This footnote will identify the number of analysts who have recently increased or decreased their earnings estimates for the company. This footnote will also identify the consensus 5-year earnings growth estimate, which is expressed on an average annual percentage basis.
Footnote B- This footnote identifies how many analysts contributed to this year's (2008) annual earnings estimate, which is printed in the annual column labeled 2008. If no analyst contributed a 2008 annual estimate, this footnote is eliminated and N/A is printed in the annual column.
Footnote C- This footnote identifies how many analysts contributed to the following year's (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 2010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.
 5. Annual rates of change (on a per-share basis) based on past actuals.
 6. Quarterly earnings are shown on a per-share basis, quarterly sales on a gross basis. *In most cases, non-recurring or extraordinary gains or losses have been omitted.* Also included are consensus mean quarterly earnings (going out three quarters), *as available.*
 7. Quarterly dividends paid are actual payments. The total of dividends paid in four quarters may not equal the figure shown in the annual series on dividends declared. (Sometimes a dividend declared at the end of the year will be paid in the first quarter of the following year.)
 8. A record of the decisions taken by the biggest institutions (over \$28 billion in equity holdings), including banks, insurance companies, mutual funds, investment advisers, internally managed endowments, and pension funds—to buy or sell during the past three quarters and the total number of shares they hold.
 9. Financial position—current and long-term assets and liabilities.
 10. The date of delivery to *Small and Mid-Cap Edition* subscribers.
 11. A summary of the business, and the company's address, telephone number, and web address.
 12. Consensus mean annual earnings estimates for the next two years, *as available.* All annual earnings estimates represent earnings from continuing operations before extraordinary, non-recurring, and special items and are consistent with current reported results. Annual earnings estimates will be accompanied by several footnotes to provide more information. (See item 4 for details).
 13. The number of shares traded monthly.
 14. Monthly price ranges of the stock—plotted on a ratio (logarithmic) grid to show percentage changes in true proportion. For example, a ratio chart equalizes the move of a \$10 stock that rises to \$11 with that of a \$100 stock that rises to \$110. Both have advanced 10% and move the same distance on a ratio grid.
 15. Relative price strength, the dotted line, describes the stock's price performance relative to the Value Line Arithmetic Average of 1700 stocks.
 16. Dividend yield—current annualized cash dividends divided by the recent price.
 17. Twelve month moving average—shows average stock price over the entire prior twelve months.
 18. Relative P/E ratio—the stock's current trailing P/E divided by the median P/E for all 3500 stocks under review.
 19. Trailing P/E ratio—the most recent price divided by the past 12 months earnings.
 20. Recent price—nine days prior to date appearing on each report.
 21. The stock's highest and lowest prices of the year.
 22. Legends/stock split table.
-

VALUE LINE SMALL AND MID-CAP SAMPLE STOCK PAGE

22 21 20 19 18 17 16 15

CANTEL MEDICAL NYSE-CMN RECENT PRICE **21.46** TRAILING P/E RATIO **26.2** RELATIVE P/E RATIO **1.57** DIV'D YLD **0.4%** **VALUE LINE**



© VALUE LINE PUBLISHING LLC	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012/2013
SALES PER SH	6.17	7.76	8.77	8.32	9.16	10.29	10.56	10.93	12.59	
"CASH FLOW" PER SH	.55	.68	.89	.72	.77	.84	1.09	1.25	1.29	
EARNINGS PER SH	.38	.47	.64	.27	.33	.35	.63	.79	.79	.66 ^A ,.75 ^C
DIV'D DECL'D PER SH	--	--	--	--	--	--	--	.07	.08	
CAP'L SPENDING PER SH	.05	.09	.15	.26	.23	.21	.17	.22	.23	
BOOK VALUE PER SH	3.35	3.95	4.83	6.10	6.49	6.96	7.60	8.36	9.17	
COMMON SHS OUTST'G (MILL)	20.95	21.92	22.51	23.10	23.91	24.25	24.63	25.06	25.55	
AVG ANN'L P/E RATIO	15.4	15.9	22.2	41.4	31.6	25.1	13.3	15.2	18.4	32.5/28.7
RELATIVE P/E RATIO	.88	.84	1.18	2.24	1.68	1.51	.88	.97	1.15	
AVG ANN'L DIV'D YIELD	--	--	--	--	--	--	--	.6%	.6%	
SALES (\$MILL)	129.3	170.0	197.4	192.2	219.0	249.4	260.1	274.0	321.7	Bold figures are consensus earnings estimates and, using the recent prices, P/E ratios.
OPERATING MARGIN	13.2%	13.6%	15.6%	13.2%	12.4%	11.9%	14.9%	16.1%	13.6%	
DEPRECIATION (\$MILL)	3.6	4.2	4.6	10.0	10.2	11.7	11.4	11.4	12.4	
NET PROFIT (\$MILL)	7.9	10.7	15.5	6.7	8.1	8.7	15.6	19.9	20.4	
INCOME TAX RATE	35.2%	38.5%	38.3%	44.3%	42.5%	37.2%	37.6%	36.8%	32.9%	
NET PROFIT MARGIN	6.1%	6.3%	7.9%	3.5%	3.7%	3.5%	6.0%	7.3%	6.4%	
WORKING CAP'L (\$MILL)	43.6	46.8	51.0	43.4	40.7	45.7	49.8	53.7	67.9	
LONG-TERM DEBT (\$MILL)	17.8	22.0	1.1	34.6	51.1	50.3	33.3	11.0	24.0	
SHR. EQUITY (\$MILL)	70.2	86.5	108.6	140.8	155.1	168.7	187.1	209.4	234.3	
RETURN ON TOTAL CAP'L	9.7%	10.6%	14.8%	5.0%	4.8%	5.0%	7.7%	9.3%	8.1%	
RETURN ON SHR. EQUITY	11.3%	12.3%	14.3%	4.7%	5.2%	5.2%	8.3%	9.5%	8.7%	
RETAINED TO COM EQ	11.3%	12.3%	14.3%	4.7%	5.2%	5.2%	8.3%	8.7%	7.8%	
ALL DIV'DS TO NET PROF	--	--	--	--	--	--	--	8%	10%	

^ANo. of analysts changing earn. est. in last 4 days: 0 up, 0 down, consensus 5-year earnings growth not available. ^BBased upon 2 analysts' estimates. ^CBased upon 2 analysts' estimates.

ANNUAL RATES				ASSETS (\$mill.)			INDUSTRY: Med Supp Non-Invasive			
of change (per share)	5 Yrs.	1 Yr.		2010	2011	10/31/11				
Sales	6.5%	15.0%		22.6	18.4	19.6	BUSINESS: Cantel Medical Corp. provides infection prevention and control products and services in the healthcare market worldwide. Its Endoscopy segment offers medical device reprocessing systems, disinfectants, detergents, and other supplies used to disinfect flexible endoscopes and other approved devices; and disposable infection control products for cleaning and sterilizing various reusable components. The Water Purification and Filtration segment provides water purification equipment and services, filtration and separation products, and disinfectants. Its Healthcare Disposables segment offers single-use, infection prevention, and control products and mail-in service and in-office spore test kits for healthcare professionals. The Dialysis segment provides medical device reprocessing systems, dialysate concentrates, and other supplies for renal dialysis. Its Therapeutic Filtration segment offers hollow fiber membrane filtration and separation technologies for medical applications. Has 1177 employees. C.E.O. & President: Andrew A. Krakauer. Address: 150 Clove Road, 9th Floor, Little Falls, NJ 07424. Tel.: (973) 890-7220. Internet: http://www.cantelmedical.com . E.B.			
"Cash Flow"	9.5%	3.0%		31.9	46.1	43.7				
Earnings	10.0%	--		34.6	40.1	46.1				
Dividends	--	20.0%		5.6	6.7	9.2				
Book Value	11.0%	10.0%		94.7	111.3	118.6				
				Property, Plant & Equip, at cost	69.7	74.7				--
				Accum Depreciation	34.5	40.2				--
				Net Property	35.2	34.5				44.2
				Other	150.8	175.6				266.4
				Total Assets	280.7	321.4				429.2

Fiscal Year	1Q	2Q	3Q	4Q	Full Year	LIABILITIES (\$mill.)
07/31/09	64.4	62.4	66.4	66.9	260.1	Accts Payable 9.6
07/31/10	71.0	66.6	66.6	69.8	274.0	Debt Due 10.0
07/31/11	72.0	81.1	82.6	86.0	321.7	Other 21.4
07/31/12	93.3					Current Liab 41.0

Fiscal Year	1Q	2Q	3Q	4Q	Full Year
07/31/08	.08	.09	.08	.10	.35
07/31/09	.13	.15	.17	.18	.63
07/31/10	.25	.19	.17	.18	.79
07/31/11	.20	.22	.19	.18	.79
07/31/12	.23	.16	.16	.18	

Cal-endar	1Q	2Q	3Q	4Q	Full Year
2009	--	--	--	--	--
2010	.033	--	.033	--	.07
2011	.04	--	.04	--	.08
2012	.047				

INSTITUTIONAL DECISIONS		
1Q'11	2Q'11	3Q'11
to Buy	44	45
to Sell	43	45
Hld's(000)	18804	19401

TOTAL SHAREHOLDER RETURN
Dividends plus appreciation as of 1/31/2012

3 Mos.	6 Mos.	1 Yr.	3 Yrs.	5 Yrs.
14.64%	26.92%	48.94%	113.25%	96.96%

©2012 Value Line Publishing LLC. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.

To subscribe call 1-800-833-0046.

TAKE ADVANTAGE OF OUR INTERNET SITE!



www.valueline.com

Value Line's Web site contains a wealth of information, including:

- ✓ stock market commentary three times a day
- ✓ stock prices
- ✓ stock price charts
- ✓ company news
- ✓ personalized portfolios
- ✓ educational features

There is also much more information
FOR SUBSCRIBERS TO THE
SMALL and MID-CAP EDITION

Officers, directors, employees and affiliates of Value Line, Inc. ("VLI"), the parent company of Value Line Publishing LLC ("VLP") and EULAV Asset Management ("EULAV"), may hold stocks that are reviewed or recommended in this publication. EULAV also manages investment companies and other accounts that use the rankings and recommendations in this publication as part of their investment strategies. These accounts, as well as the officers, directors, employees and affiliates of VLI, may dispose of a security notwithstanding the fact that The Value Line Investment Survey (the "Survey") ranks the issuer favorably; conversely, such accounts or persons may purchase or hold a security that is poorly ranked by the Survey. Some of the investment companies managed by EULAV only hold securities with a specified minimum Timeliness Rank by the Survey and dispose of those positions when the Timeliness Rank declines or is suspended. Subscribers to the Survey and its related publications as well as some institutional customers of VLP will have access to the entire Value Line Investment Survey at 8:00 AM each Monday (or the next business day after a Monday when the New York Stock Exchange is closed). At the same time, portfolio managers for EULAV will receive reports providing Timeliness Ranking information. EULAV's portfolio managers also may have access to publicly available information that may ultimately result in or influence a change in rankings or recommendations, such as earnings releases, changes in market value or disclosure of corporate transactions. The investment companies or accounts may trade upon such information prior to a change in ranking. While the rankings in the Survey are intended to be predictive of future relative performance of an issuer's securities, the Survey is not intended to constitute a recommendation of any specific security. Any investment decision with respect to any issuer covered by the Survey should be made as part of a diversified portfolio of equity securities and in light of an investor's particular investment objectives and circumstances. Value Line, Value Line logo, The Value Line Investment Survey, Timeliness are trademarks of Value Line, Inc.